#United States #Bridgewater #Insmed #ARIKAYCE #Samuele Butera

Insmed Welcomes Samuele Butera as Senior Vice President for Global Respiratory Division

In a significant move aimed at enhancing its leadership in the respiratory therapeutic area, Insmed Incorporated has appointed Samuele Butera as Senior Vice President and General Manager for Global Respiratory, effective immediately. The company, listed on Nasdaq under the symbol INSM, is known for its commitment to developing leading-edge therapies designed to transform the lives of patients battling serious illnesses.

Mr. Butera will oversee Insmed's Respiratory Therapeutic Area, reporting directly to Will Lewis, the Chair and CEO of Insmed. His appointment comes at a crucial time for the company as it aims to build upon its existing successes, particularly with products like BRINSUPRI and ARIKAYCE. Will Lewis expressed enthusiasm about the addition of Mr. Butera to the team, citing his extensive commercial experience and proven track record in driving high-performance teams through challenging market landscapes.

Having spent over 20 years in diverse leadership positions, Butera's most recent role was President of Pulmonary Hypertension and Retina at Johnson & Johnson. His tenure there was marked by significant growth in a multi-billion-dollar business unit and the successful launch of OPSYNVI®, which combines the drugs macitentan and tadalafil. His leadership experience extends further back to his role as Worldwide Vice President for Infectious Diseases and Vaccines at Johnson & Johnson, where he played a pivotal role in launching COVID vaccines, reflecting his ability to strategize and execute in various therapeutic segments.

Before his impactful years at Johnson & Johnson, Mr. Butera held senior roles at Novartis, including Global Head of Cell and Gene Therapies. His key achievement there was leading the launch of KYMRIAH®, the first CAR-T therapy, marking a significant milestone in cancer treatment. With earlier roles that include experiences at McKinsey & Company and Goldman Sachs, Butera's multifaceted background encompasses strategy, finance, and global health, positioning him well for his new responsibilities at Insmed. He holds a Master in Public Policy from Harvard University and a Bachelor of Science in International Economics from Università Bocconi in Milan, Italy.

Reflecting on his new role, Mr. Butera stated, “I am incredibly excited to join Insmed and lead the Respiratory Therapeutic Area at such a defining moment for the Company. Insmed has built a respiratory portfolio and pipeline that have the potential to meaningfully change the lives of patients.” He aims to not only advance the successful launch of BRINSUPRI but also to explore opportunities for the growth of ARIKAYCE through label expansion and continue the development of other promising candidates for those who need them most.

About Insmed

Insmed Incorporated is recognized as a people-first global biopharmaceutical organization, dedicated to bringing first- and best-in-class therapies to the forefront of patient care. The company is progressing a diverse array of medicines at various stages, focusing on the growing need for innovative treatments in the respiratory and other therapeutic areas. Insmed's work encompasses three main therapeutic categories: Respiratory, Immunology & Inflammation, and Neurology & Rare Conditions.

Headquartered in Bridgewater, New Jersey, Insmed operates internationally with offices and research facilities throughout the United States, Europe, and Japan. The company has been acknowledged as one of the best employers in the biopharmaceutical sector and has spent five consecutive years ranked as the number one Science Top Employer. For more information about Insmed and its groundbreaking work, visit www.insmed.com as well as follow Insmed on platforms like LinkedIn, Instagram, YouTube, and X.